Kogenate (BAY14-2222)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hematologic Disease
Conditions
Hematologic Disease, Hemophilia A
Trial Timeline
Feb 1, 2006 → Mar 1, 2008
NCT ID
NCT00586521About Kogenate (BAY14-2222)
Kogenate (BAY14-2222) is a approved stage product being developed by Bayer for Hematologic Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00586521. Target conditions include Hematologic Disease, Hemophilia A.
What happened to similar drugs?
0 of 4 similar drugs in Hematologic Disease were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00586521 | Approved | Completed |
| NCT00606060 | Phase 3 | Completed |
| NCT00864552 | Pre-clinical | Completed |
Competing Products
20 competing products in Hematologic Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 39 |
| RLYB116 for Injection | Rallybio | Phase 1 | 19 |
| DS3790a + Combination drug + Combination drug | Daiichi Sankyo | Phase 1/2 | 39 |
| Isavuconazole | Astellas Pharma | Phase 2 | 35 |
| isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral | Astellas Pharma | Phase 1 | 29 |
| DSP-5336 + [14C]-DSP-5336 | Sumitomo Pharma | Phase 1 | 36 |
| BBI608 + Dexamethasone + Bortezomib + Imatinib + Ibrutinib | Sumitomo Pharma | Phase 1 | 29 |
| Venetoclax + ethinyl estradiol/levonorgestrel | AbbVie | Phase 1 | 36 |
| ABT-888 + Temozolomide | AbbVie | Phase 1 | 29 |
| ABBV-101 | AbbVie | Phase 1 | 36 |
| elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injection | AbbVie | Phase 2 | 35 |
| Capivasertib + Rabeprazole | AstraZeneca | Phase 1 | 29 |
| AZD9829 + AZD9829 | AstraZeneca | Phase 1/2 | 36 |
| ridaforolimus | Merck | Phase 2 | 35 |
| Pembrolizumab/vibostolimab coformulation | Merck | Phase 2 | 35 |
| Nemtabrutinib | Merck | Phase 1 | 29 |
| Ondansetron + Aprepitant | Merck | Phase 2 | 35 |
| Nemtabrutinib | Merck | Phase 2 | 42 |
| ARQ 621 | Merck | Phase 1 | 29 |
| Nemtabrutinib | Merck | Phase 1 | 33 |